Allurion Technologies (ALUR) Net Income towards Common Stockholders (2022 - 2026)
Allurion Technologies (ALUR) posted Net Income towards Common Stockholders of -$6.1 million for Q1 2026, up 2.96% on a QoQ basis from -$6.3 million in Q4 2025, and down 182.6% year-over-year from $7.4 million in Q1 2025.
Allurion Technologies (ALUR) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Allurion Technologies' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$6.1 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 182.6% year-over-year to -$6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.6 million (down 1750.96% YoY) and the FY2025 annual result came in at -$29.0 million, down 302.25% from the prior year.
- Net Income towards Common Stockholders was -$6.1 million for Q1 2026 at Allurion Technologies, up from -$6.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $8.7 million in Q3 2024 and bottomed at -$22.7 million in Q2 2023.
- A 5-year average of -$9.5 million and a median of -$9.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 270.65% — and 2025, when it jumped 269.69%.
- Allurion Technologies' Net Income towards Common Stockholders stood at -$13.1 million in 2022, then tumbled by 63.53% to -$21.4 million in 2023, then jumped by 55.08% to -$9.6 million in 2024, then surged by 34.63% to -$6.3 million in 2025, then climbed by 2.96% to -$6.1 million in 2026.
- Business Quant data shows ALUR's Net Income towards Common Stockholders at -$6.1 million in Q1 2026, -$6.3 million in Q4 2025, and -$11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Allurion Technologies | 74.67 Mn | 69.62 Mn | 1.23 Mn | -6.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.10 Mn |
| Dec 31, 2025 | -6.28 Mn |
| Sep 30, 2025 | -11.88 Mn |
| Jun 30, 2025 | -9.34 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | -9.61 Mn |
| Sep 30, 2024 | 8.74 Mn |
| Jun 30, 2024 | -8.32 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | -21.39 Mn |
| Sep 30, 2023 | -21.89 Mn |
| Jun 30, 2023 | -22.72 Mn |
| Mar 31, 2023 | -18.52 Mn |
| Dec 31, 2022 | -13.08 Mn |
| Sep 30, 2022 | -14.31 Mn |
| Jun 30, 2022 | -6.13 Mn |